Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

How Quickly Does IVIg Work for Multifocal Motor Neuropathy?

At a Glance

For multifocal motor neuropathy, many people first notice stronger muscles 3 to 4 weeks after initial IVIg infusions, but improvement may take several months. Treatment can also be successful when it prevents further weakness instead of restoring strength already lost.

The short answer is that many patients notice their first improvements in muscle strength within 3 to 4 weeks of their initial Intravenous Immunoglobulin (IVIg) loading doses [1][2]. However, treatment response is highly individual. For some, it can take several months of regular maintenance infusions to see a noticeable difference in their daily function, and for others, a successful response means stabilizing the disease and preventing further weakness rather than regaining lost strength [1][3].

The First Month (Initial Loading Doses)

When you begin IVIg for Multifocal Motor Neuropathy (MMN), you typically receive a high induction dose (often around 2 grams per kilogram of body weight) spread over several consecutive days [4]. The goal of this initial treatment is to modulate your immune system and reduce immune-mediated injury to your motor nerves.

You should not expect overnight results. In one observational study, about 75% of patients demonstrated at least a mild, measurable improvement in their muscle strength by day 30 [1]. Because early changes can be detected around this time, neurologists generally use the 3- to 4-week mark as an initial milestone to evaluate whether the IVIg is beginning to work [1][2].

The Next 3 to 6 Months (Maintenance Phase)

If you do not feel stronger in the first month, it does not automatically mean the treatment has failed [5][1]. Your neurologist will evaluate your specific situation and objective measurements before making changes. After your initial doses, you will transition to maintenance infusions. These are individualized based on your response, but regimens often range from every 3 to 8 weeks depending on the exact dosage used [4][6][7].

During this maintenance phase, improvements can continue to build over time. Clinical studies show that some patient groups record better strength and functional scores at the 6-month mark than they do at 30 days [1].

As you continue with maintenance, you may notice a wearing-off effect—a pattern where your strength dips slightly just before your next scheduled infusion [8]. If you experience this, report it to your doctor. Your neurologist may adjust your dose or shorten the time between infusions to keep your strength stable [9][10]. Never attempt to change, delay, or stop your infusion schedule on your own.

What Impacts Your Response Speed?

Several factors influence how your muscles respond to IVIg:

  • Duration of weakness: Muscles that have only recently become weak tend to have a faster and larger response to IVIg [11].
  • Nerve Damage and Shrinkage: If a muscle has been weak for a very long time and has visible shrinking (called atrophy), this can be a sign of deeper nerve damage known as axonal loss [12]. While atrophy can also result from simple disuse, your doctor may use EMG (electromyography) and nerve conduction studies to confirm whether axonal loss has occurred. Muscles with significant axonal loss may take much longer to recover, or they may not regain their full original strength [13].

To accurately track your progress, your neurologist will combine your personal reports of daily function and fatigue with objective measurements like grip strength devices or specialized manual muscle testing [14][3].

(Note: While tracking your strength, you should also monitor for acute side effects. If you develop severe headaches, chest pain, breathing difficulties, or allergic reactions shortly after an infusion, seek immediate medical care, as these require prompt attention separate from your routine MMN tracking [8].)

Common questions in this guide

How soon might IVIg improve strength in MMN?
Many people notice their first improvement in muscle strength about 3 to 4 weeks after the initial IVIg loading doses. The timing varies, and some people need several months of regular maintenance infusions before daily activities become easier.
Does no improvement after the first month mean IVIg has failed?
Not necessarily. Some people improve gradually during the next 3 to 6 months, while others respond by stabilizing their strength and preventing further weakness rather than regaining strength already lost. Your neurologist will use your symptoms and objective strength measurements to guide decisions.
How often are maintenance IVIg infusions given for MMN?
Maintenance schedules are individualized, but infusions are often given every 3 to 8 weeks. The dose and timing may be adjusted according to how long the benefit lasts and whether weakness returns before the next infusion.
What should I do if my strength drops before my next IVIg infusion?
Tell your neurologist about the timing and severity of the change. A wearing-off pattern may lead the clinician to adjust the dose or shorten the interval, but you should not change, delay, or stop infusions on your own.
Can long-standing weakness limit how much strength I regain?
Yes. Muscle atrophy and long-term nerve damage involving axonal loss can slow recovery or limit how much strength returns. Electromyography and nerve conduction studies may help your neurologist assess whether this type of damage is present.
How will my neurologist measure whether IVIg is working?
Your neurologist may combine your report of daily activities and fatigue with objective tests such as grip-strength measurements and manual muscle testing. Tracking the same tasks and measurements over time can show improvement or stabilization even when changes are gradual.

Get notified when new evidence is published on Multifocal motor neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    High-dose Ig VENA is well tolerated and efficacious in patients with multifocal motor neuropathy.

    Nobile-Orazio E, Cocito D, Briani C, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2017; (38(5)):899-902 doi:10.1007/s10072-017-2826-8.

    PMID: 28144763
  2. 2

    Patterns of motor nerve demyelination and their prognostic significance in multifocal motor neuropathy.

    Posa A, Emmer A, Biefel T, Kornhuber ME

    IBRO neuroscience reports 2026; (20()):474-479 doi:10.1016/j.ibneur.2026.03.005.

    PMID: 41890222
  3. 3

    Outcome measures in MMN revisited: further improvement needed.

    Pruppers MH, Draak TH, Vanhoutte EK, et al.

    Journal of the peripheral nervous system : JPNS 2015; (20(3)):306-18 doi:10.1111/jns.12124.

    PMID: 26115442
  4. 4

    Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi-center, open-label, 52-week phase 3 trial.

    Kuwabara S, Misawa S, Mori M, et al.

    Journal of the peripheral nervous system : JPNS 2018; (23(2)):115-119 doi:10.1111/jns.12268.

    PMID: 29635876
  5. 5

    Revisiting multifocal motor neuropathy: mechanisms, diagnosis and future directions.

    Dubuisson NJ, Rajabally YA, Philips C, et al.

    Brain : a journal of neurology 2026; doi:10.1093/brain/awag260.

    PMID: 42522566
  6. 6

    IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: A randomised, double-blind, multi-center cross-over non-inferiority study vs Kiovig®-The LIME Study.

    Léger JM, Alfa Cissé O, Cocito D, et al.

    Journal of the peripheral nervous system : JPNS 2019; (24(1)):56-63 doi:10.1111/jns.12291.

    PMID: 30456899
  7. 7

    Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry.

    Stangel M, Gold R, Pittrow D, et al.

    Therapeutic advances in neurological disorders 2016; (9(3)):165-79 doi:10.1177/1756285616629869.

    PMID: 27134672
  8. 8

    Immunoglobulin for multifocal motor neuropathy.

    Keddie S, Eftimov F, van den Berg LH, et al.

    The Cochrane database of systematic reviews 2022; (1()):CD004429 doi:10.1002/14651858.CD004429.pub3.

    PMID: 35015296
  9. 9

    Dose, exposure, and treatment regimen of intravenous immunoglobulin G in multifocal motor neuropathy.

    Li Z, Roepcke S, Franke R, Yel L

    Frontiers in neurology 2024; (15()):1478419 doi:10.3389/fneur.2024.1478419.

    PMID: 39574508
  10. 10

    Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy.

    Li Z, Roepcke S, Franke R, Yel L

    Annals of clinical and translational neurology 2024; (11(8)):1977-1987 doi:10.1002/acn3.52098.

    PMID: 38978354
  11. 11

    Pattern of muscle strength improvement after intravenous immunoglobulin therapy in multifocal motor neuropathy.

    Bakers JNE, van Eijk RPA, van den Berg LH, et al.

    Muscle & nerve 2021; (63(5)):678-682 doi:10.1002/mus.27185.

    PMID: 33501670
  12. 12

    Prevention of axonal loss after immediate dosage titration of immunoglobulin in multifocal motor neuropathy.

    Al-Zuhairy A, Jakobsen J, Krarup C

    European journal of neurology 2024; (31(7)):e16305 doi:10.1111/ene.16305.

    PMID: 38651498
  13. 13

    [Analysis of the clinical and electrophysiological characteristics of multifocal motor neuropathy].

    Wang HF, Yang F, Cui F, et al.

    Zhonghua nei ke za zhi 2017; (56(11)):842-845 doi:10.3760/cma.j.issn.0578-1426.2017.11.013.

    PMID: 29136715
  14. 14

    Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy.

    Doneddu PE, Mandia D, Gentile F, et al.

    Journal of the peripheral nervous system : JPNS 2020; (25(3)):238-246 doi:10.1111/jns.12396.

    PMID: 32470190

This page explains the usual timeline for an IVIg response in MMN for educational purposes and does not replace medical advice. Your neurologist should interpret your response and adjust treatment safely.